Pulse Biosciences (NASDAQ:PLSE) Trading Down 8%

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price was down 8% during trading on Wednesday . The company traded as low as $17.70 and last traded at $17.73. Approximately 44,112 shares were traded during trading, a decline of 80% from the average daily volume of 221,422 shares. The stock had previously closed at $19.28.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research report on Thursday, July 11th.

Pulse Biosciences Stock Performance

The company has a market capitalization of $905.61 million, a price-to-earnings ratio of -22.54 and a beta of 1.75. The business’s 50-day simple moving average is $11.82 and its 200-day simple moving average is $9.80.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.17) earnings per share for the quarter.

Insider Activity at Pulse Biosciences

In other news, CEO Burke Thomas Barrett purchased 10,000 shares of the business’s stock in a transaction that occurred on Monday, May 20th. The shares were acquired at an average cost of $8.56 per share, for a total transaction of $85,600.00. Following the transaction, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at approximately $85,600. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 71.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Pulse Biosciences

Several hedge funds have recently bought and sold shares of PLSE. Vanguard Group Inc. grew its stake in shares of Pulse Biosciences by 28.8% during the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after acquiring an additional 189,227 shares in the last quarter. Griffin Asset Management Inc. grew its stake in shares of Pulse Biosciences by 15.7% during the 1st quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock worth $2,616,000 after acquiring an additional 40,700 shares in the last quarter. Inspire Investing LLC grew its stake in shares of Pulse Biosciences by 32.1% during the 1st quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock worth $360,000 after acquiring an additional 10,039 shares in the last quarter. PNC Financial Services Group Inc. bought a new position in shares of Pulse Biosciences during the 4th quarter worth approximately $242,000. Finally, Cetera Advisors LLC bought a new position in shares of Pulse Biosciences during the 1st quarter worth approximately $109,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.